SCHEMBL13069472

SCHEMBL13069472

CC(C)(Oc1ccc(Oc2ccc3c(-c4ccc(Cl)cc4)noc3c2)cc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 16/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ PPARG P37231 11/20 0.48
▸ FABP2 P12104 1/20 0.48
▸ SLC22A12 Q96S37 1/20 0.48
▸ PDE5A O76074 1/20 0.47
▸ MAP4K4 O95819 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ MINK1 Q8N4C8 1/20 0.47
▸ PPARD Q03181 11/20 0.45
▸ CDH1 P12830 1/20 0.45
▸ CTNNB1 P35222 1/20 0.45
▸ TCF7L2 Q9NQB0 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10662939 0.93 PPARA (0.55) PPARAMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL3378784 0.93 PPARA (0.47) PPARAMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL3376815 0.88 PPARA (0.53) PPARAPPARGPPARD
SCHEMBL3377036 0.84 PPARG (0.47) PPARAMEN1CYP2C19KMT2APPARG
SCHEMBL3410208 0.83 PPARA (0.48) PPARAPPARGPPARDCTNNB1FABP1
SCHEMBL13069647 0.82 PPARG (0.46) PPARAMEN1CYP2C19KMT2APPARG
SCHEMBL3379784 0.81 PPARD (0.46) PPARAMEN1CYP2C19KMT2APPARG
SCHEMBL3376896 0.81 PPARD (0.53) PPARAPPARGPPARD
SCHEMBL10660550 0.81 PPARA (0.43) PPARAMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL10658222 0.81 ESR1 (0.41) PPARAMEN1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796665-B1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK SHARP & DOHME (US) 2010-11-17 — — EP disclosed
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 — — US disclosed
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 — — US disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 — — US disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders LIPA, APOB, LCAT PPARA 111/4885MEN1 2918/4885CYP1A2 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback